$18.04 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter

Brokerages expect Veru Inc. (NASDAQ:VERU – Get Rating) to post sales of $18.04 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Veru’s earnings. The highest sales estimate is $18.90 million and the lowest is $17.10 million. Veru posted sales of $17.66 million in the same quarter last year, which suggests a positive year-over-year growth rate of 2.2%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Veru will report full year sales of $75.51 million for the current year, with estimates ranging from $64.80 million to $100.00 million. For the next fiscal year, analysts forecast that the business will post sales of $95.08 million, with estimates ranging from $75.02 million to $126.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Veru.

Veru (NASDAQ:VERU – Get Rating) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Veru had a negative return on equity of 18.15% and a negative net margin of 45.56%. During the same period in the previous year, the company earned ($0.04) EPS.

VERU has been the subject of a number of analyst reports. Zacks Investment Research cut Veru from a “buy” rating to a “hold” rating in a research note on Thursday, April 21st. Oppenheimer upped their price objective on Veru from $25.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 12th. HC Wainwright upped their price objective on Veru from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 12th. TheStreet upgraded Veru from a “d+” rating to a “c” rating in a report on Friday, April 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Veru in a report on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $32.75.

Hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its position in shares of Veru by 833.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,600 shares of the company’s stock worth $49,000 after buying an additional 5,000 shares in the last quarter. Ensign Peak Advisors Inc bought a new stake in Veru during the 4th quarter valued at $51,000. Josh Arnold Investment Consultant LLC bought a new stake in Veru during the 4th quarter valued at $59,000. Bridgefront Capital LLC purchased a new position in shares of Veru during the 4th quarter valued at $63,000. Finally, XTX Topco Ltd grew its position in shares of Veru by 18.7% during the 1st quarter. XTX Topco Ltd now owns 14,426 shares of the company’s stock valued at $70,000 after purchasing an additional 2,270 shares in the last quarter. 29.11% of the stock is owned by hedge funds and other institutional investors.

Veru stock opened at $13.00 on Monday. The business has a 50 day simple moving average of $8.17 and a 200 day simple moving average of $7.04. Veru has a one year low of $4.34 and a one year high of $17.50. The company has a market capitalization of $1.04 billion, a PE ratio of -38.23 and a beta of -0.57.

Veru Company Profile (Get Rating)

Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.

Further Reading